Edwards Lifesciences Corporation (EW) AI Stock Analysis

Edwards Lifesciences Corporation is a global medical technology company focused on structural heart disease, critical care, and surgical monitoring. Headquartered in Irvine, California, it develops minimally invasive solutions that include transcatheter heart valve replacement systems and repair products for mitral and tricuspid valve conditions. Its surgical structural heart portfolio features brands such as INSPIRIS and KONECT RESILIA for aortic valve and root replacements, as well as the HARPOON Beating Heart Mitral Valve Repair System. In addition, the company provides critical care technologies, including advanced hemodynamic monitoring systems that measure heart function and fluid status in surgical and intensive care settings.

Edwards Lifesciences expanded revenue from $5.23B in FY2021 to $6.07B in FY2025, delivering a five-year revenue CAGR of 6.7%. Growth fluctuated over this period, rising 11.6% in FY2023, declining 9.4% in FY2024 to $5.44B, and rebounding 11.5% in FY2025. Gross margins remained stable, registering at 78.1% in FY2025. Operating margins were 27.0% in FY2025 and reached 29.8% over the trailing twelve months. Net income was $1.07B in FY2025, down from a peak of $4.17B in FY2024. In the latest quarter ended June 30, 2026, quarterly revenue grew 13.6% year-over-year, while quarterly earnings declined 25.4%.

As of June 30, 2026, Edwards Lifesciences held $4.25B in cash and short-term investments against $704.4M in total debt, yielding a net cash position of $3.55B. Its debt-to-equity ratio stood at 0.07, and the current ratio was 4.52. In FY2025, operating cash flow recovered to $1.60B and free cash flow reached $1.33B. Capital expenditures totaled $260.2M in FY2025. The company deployed cash toward share repurchases, spending $893.4M on buybacks in FY2025, contributing to an 8.6% reduction in its share count over five years.

Edwards Lifesciences trades at a trailing P/E of 51.5x and a forward P/E of 25.6x, compared to medians of 27.2x and 16.5x for its S&P 500 Healthcare peers. Its enterprise value stands at $46.49B, with an EV/EBITDA multiple of 28.1x compared to the peer median of 15.0x. The stock carries a price-to-sales ratio of 7.7x versus the peer median of 3.4x, alongside a PEG ratio of 1.85. Over the trailing 12 months, the stock gained 19.2%, outperforming the S&P 500 ETF (SPY) return of 16.8%, but its 5-year return of -22.8% lagged the broader market's 83.0% gain.

Wall Street analysts hold 18 Strong Buy, 5 Buy, and 6 Hold ratings on Edwards Lifesciences, with no Sell or Strong Sell recommendations. The mean price target is $101.81, representing a 17.6% upside from the last closing price of $86.60. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $6.76B and EPS of $3.00, reflecting 17.2% earnings growth. For next fiscal year, 28 analysts project revenue of $7.43B and EPS of $3.38. The company beat EPS estimates in 3 of the last 4 quarters, with its next earnings report scheduled for November 4, 2026.

This page is an AI-written research summary of Edwards Lifesciences Corporation (EW). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: EW income statement, EW balance sheet, EW key metrics, EW analyst forecast, EW chart. See the EW stock overview for the latest quote and news.